2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Wednesday, November 16, 2016

11:00AM-12:30PM: Abstract Number: 3203

Analysis of Efficacy and Safety of Cyclophosphamide in Juvenile Dermatomyositis Using a Large National UK Cohort

Pediatric Rheumatology – Clinical and Therapeutic Aspects III: Autoinflammatory Diseases and Juvenile Dermatomyositis

11:00AM-12:30PM: Abstract Number: 3215

ASK1 Is Regulated By IL-1β and TNF and Modulates Key Rheumatoid Arthritis (RA) Fibroblast-like Synoviocyte Functions (FLS)

Rheumatoid Arthritis – Human Etiology and Pathogenesis II

11:00AM-12:30PM: Abstract Number: 3213

Assessment of Two Different DAS Treatment Targets in Early Active Rheumatoid Arthritis Patients

Rheumatoid Arthritis – Clinical Aspects VII: The Impact of Treating to Target

11:00AM-12:30PM: Abstract Number: 3188

Association of Gout with Risk of Advanced Chronic Kidney Disease

Epidemiology and Public Health III: Psoriatic Arthritis and More

11:00AM-12:30PM: Abstract Number: 3204

Body Composition and Adipose Tissue Distribution in Juvenile Dermatomyositis and Associations with Cardiac Function

Pediatric Rheumatology – Clinical and Therapeutic Aspects III: Autoinflammatory Diseases and Juvenile Dermatomyositis

11:00AM-12:30PM: Abstract Number: 3229

Bone Morphogenetic Protein 6 Receptor Inhibition Restores Salivary Gland Function in a Mouse Model of Primary Sjögren’s Syndrome

Sjögren's Syndrome II: Basic Insights

11:00AM-12:30PM: Abstract Number: 3217

Broad-Based Interrogation of the Serum Proteome Suggests That RA Onset Is Associated with Activation of the Intrinsic Coagulation Cascade

Rheumatoid Arthritis – Human Etiology and Pathogenesis II

11:00AM-12:30PM: Abstract Number: 3209

Clinical and Radiological Outcomes of 5 Years Remission Steered Treatment in Early Rheumatoid and Undifferentiated Arthritis Patients

Rheumatoid Arthritis – Clinical Aspects VII: The Impact of Treating to Target

11:00AM-12:30PM: Abstract Number: 3202

Clinical and Ultrasonographic Evaluation of Joint Involvement in Patients with Systemic Sclerosis

Imaging of Rheumatic Diseases III: Crystal Arthritis, Osteoarthritis, Connective Tissue Disease and Vasculitis

11:00AM-12:30PM: Abstract Number: 3252

Content Analysis of Ergonomic Recommendations Using the Ergonomic Assessment Tool for Arthritis

ARHP VI: Rehabilitation Sciences

11:00AM-12:30PM: Abstract Number: 3191

Coronary Revascularization Procedure Rates and Risks Among Patients with Systemic Lupus Erythematosus Compared to Those with Diabetes Mellitus in a Nationwide Medicaid Cohort

Health Services Research II

11:00AM-12:30PM: Abstract Number: 3232

Decreased Expression of Micro-RNA 130a and Micro-RNA 708 in Type-1 Classical Dendritic Cells of Patients with Primary SS Indicates Their Dysregulation

Sjögren's Syndrome II: Basic Insights

11:00AM-12:30PM: Abstract Number: 3238

Depression Symptoms throughout the Lifespan in a Low-Income, Minority Cohort of Lupus Patients: Who Is at Risk?

Systemic Lupus Erythematosus – Clinical Aspects and Treatment VI: Quality of Life

11:00AM-12:30PM: Abstract Number: 3233

Determinants of Pain, Fatigue, Physical Function and Social Participation in SLE Patients, Measured with Patient Reported Outcomes Measurement Information System (PROMIS®) Computerized Adaptive Tests

Systemic Lupus Erythematosus – Clinical Aspects and Treatment VI: Quality of Life

11:00AM-12:30PM: Abstract Number: 3186

Determinants of Patient-Physician Discordance in Global Assessment in Psoriatic Arthritis and Levels of Discordance According to Disease Activity: A Multicenter European Study

Epidemiology and Public Health III: Psoriatic Arthritis and More

«Previous Page
1
…
4
5
6
7
8
…
10
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].